LONDON (Alliance News) - GlaxoSmithKline PLC on Tuesday said it has received positive data on the efficacy and safety of its Incruse Ellipta treatment for patients with chronic obstructive pulmonary disease.
The results from the randomised, blinded 201316 study of the treatment showed a once-daily dose of Incruse Ellipta showed a statistically significant improvement in lung function against tiotropium, while study 201315 showed the treatment was not inferior to glycopyrronium.
Tiotropium and glycopyrronium are two existing treatment for COPD.
Shares in Glaxo were up 0.7% to 1,354.00 pence on Tuesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)